CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Find out Which Has Higher Fees Index Fund Or Target Date to prevent hidden costs. This overview covers expense drivers and decision tips.
28,473 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Oracle reports a powerful cloud quarter and record backlog, signaling a potential future milestone. Yet mounting capi...
Ethereum breached a critical support level, signaling renewed downside risk. This report breaks down the factors, key...
Greg Abel is moving Berkshire Hathaway beyond its familiar bets. After a bold $23 billion purchase in a single stock,...
More than 60 analysts now rate the stock Buy as investors await the upcoming earnings release and assess cloud, adver...
Palantir reports strong government revenue growth while warning that adversaries are increasingly targeting AI data c...
Corporate treasuries are redefining crypto investing. This deep dive looks at how Strategy amassed a sizable Bitcoin ...
In a challenging crypto bear market, XRP and Dogecoin face different hurdles and opportunities. This guide breaks dow...
A fresh Wall Street call boosts Broadcom stock, signaling a potential historic buy as AI chip demand and a multi-year...
A late-night scam turned into a £70,000 headache for a prominent tech reviewer. This article breaks down how the trap...
Standard Chartered unveils a bold UNI price forecast for 2030, arguing tokenized assets will push DeFi liquidity to t...
Oracle's AI strategy is under scrutiny as earnings shed light on backlog and cash needs. We see roughly 46-47% upside...